N. B. Leighl

机构：University Health Network, Princess Margaret Cancer Centre

发表论文 77 篇 · 总被引 1019 次 · h-index 12

代表论文

• Biomarkers That Currently Affect Clinical Practice: EGFR, ALK, MET, KRAS (2012 · Current Oncology · 被引 56)
• 1192MO Amivantamab monotherapy and in combination with lazertinib in post-osimertinib EGFR-mutant NSCLC: Analysis from the CHRYSALIS study (2021 · Annals of Oncology · 被引 32)
• Interim report of on-study demographics and toxicity from E1505, a phase III randomized trial of adjuvant (adj) chemotherapy (chemo) with or without bevacizumab (B) for completely resected early-stage non-small cell lung cancer (NSCLC). (2011 · Journal of Clinical Oncology · 被引 32)
• An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second-/third-line therapy in advanced non-small-cell lung cancer (2011 · Annals of Oncology · 被引 29)
• Phase II study of PRO95780 plus paclitaxel, carboplatin, and bevacizumab (PCB) in non-small cell lung cancer (NSCLC). (2010 · Journal of Clinical Oncology · 被引 20)
• An Ontario Clinical Oncology Group (OCOG) randomized trial (PET START) of FDG PET/CT in patients with stage III non-small cell lung cancer (NSCLC): Predictors of overall survival. (2011 · Journal of Clinical Oncology · 被引 14)